Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.17843/rpmesp.2021.381.6627 http://scihub22266oqcxt.onion/10.17843/rpmesp.2021.381.6627 34190912!ä!34190912 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Peru+Med+Exp+Salud+Publica 2021 ; 38 (1): 171-177 Nephropedia Template TP {{tp|p=34190912|t=2021. La regulacion de los ensayos clinicos para la COVID-19 en el Peru |pdf=|usr=}}{{34190912}} gab.com Text La regulacion de los ensayos clinicos para la COVID-19 en el Peru JO: Rev Peru Med Exp Salud Publica http://www.kidney.de/pget.php?&tw=1&pmid=34190912 #FOAvip COVID-19 has affected the conduct of clinical trials worldwide. Once the health emergency began in Peru, the national government took measures to guarantee the conduct of COVID-19 clinical trials. A national research ethics committee was exclusively established for COVID-19 clinical trials; and a regulatory framework was implemented to ensure the ethical and timely conduct of these studies. To december 31, 2020, the Peruvian National Health Institute authorized 29 clinical trials, of which 4 test vaccines. The mean and standard deviation of time authorization were 19.3 and 10.5 days, respectively. 58.6% (n= 17) were phase II clinical trials and 34.5% (n= 10) were phase III; 31.0% (n= 9) were sponsored by a Peruvian institution. The aim of the actions implemented was to promote COVID-19 research while responding to the health emergency needs without affecting the protection of participants or the rigor of the studies. Twit Text FOAVip La regulacion de los ensayos clinicos para la COVID-19 en el Peru ????Rev Peru Med Exp Salud Publica http://www.kidney.de/pget.php?&tw=1&pmid=34190912 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34190912 #FOAvip English Wikipedia <ref>{{Cite pmid|34190912}}</ref> La regulacion de los ensayos clinicos para la COVID-19 en el Peru #MMPMID34190912 Lope PC; Carracedo S; Romani F Rev Peru Med Exp Salud Publica 2021[Jan]; 38 (1): 171-177 PMID34190912show ga COVID-19 has affected the conduct of clinical trials worldwide. Once the health emergency began in Peru, the national government took measures to guarantee the conduct of COVID-19 clinical trials. A national research ethics committee was exclusively established for COVID-19 clinical trials; and a regulatory framework was implemented to ensure the ethical and timely conduct of these studies. To december 31, 2020, the Peruvian National Health Institute authorized 29 clinical trials, of which 4 test vaccines. The mean and standard deviation of time authorization were 19.3 and 10.5 days, respectively. 58.6% (n= 17) were phase II clinical trials and 34.5% (n= 10) were phase III; 31.0% (n= 9) were sponsored by a Peruvian institution. The aim of the actions implemented was to promote COVID-19 research while responding to the health emergency needs without affecting the protection of participants or the rigor of the studies. |*COVID-19[MESH] |Ethics Committees, Research[MESH] |Humans[MESH] |Peru[MESH]La regulacion de los ensayos clinicos para la COVID-19 en el Peru (epmc).pdf DeepDyve Pubget Overpricing